Characteristic Study on Chinese Patients With Multiple Sclerosis

Sun Yat-sen University

Status

Unknown

Conditions

Multiple Sclerosis

Treatments

Drug: atorvastatin

Drug: EPO

Drug: β-interferon

Study type

Interventional

Funder types

Other

Identifiers

NCT00818103

2007027

Details and patient eligibility

About

Compared with MS in white populations, in people of China descent multiple sclerosis (MS)is characterized by lower prevalence, more frequent and severe involvement of the visual system at onset and during the entire clinical course, more common occurrence of optic and spinal involvement, relatively rapid progression and less common occurrence of a progressive course. Data are not available for mainland China that are focused on characteristic studies of MS. In this study, the investigators sought to explore the characteristics of MS among Chinese in China, by conducting a study on genetics, pathogenesis, pathology, neuroimaging characteristics, and so on. Based on these data, the investigators try to explore the difference in neuromyelitis optical (NMO) and MS and provide clinical data for treatment guidelines for NNO and MS.

Enrollment

600 estimated patients

Sex

All

Ages

Under 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Criteria for neuromyelitis optical
- Optic neuritis
- Acute myelitis
At least two of three supportive criteria:
- Contiguous spinal cord MRI lesion extending over >= 3 vertebral segments
- Brain MRI not meeting diagnostic criteria for multiple sclerosis
- NMO-IgG seropositive status
Criteria for multiple sclerosis:
- Two or more attacks; objective clinical evidence of two or more lesions, OR
- Two or more attacks; objective clinical evidence of one lesion, dissemination in space, demonstrated by: MRI or two or more MRI-detected lesions consistent with MS plus positive CSF or wait further clinical attack implicating a different site, OR
- One attack; objective clinical evidence of two or more lesions, dissemination in time, demonstrated by: MRI or second clinical attack, OR
- One attack; objective clinical evidence of one lesion (monosymptomatic presentation; clinically isolated syndrome), dissemination in space, demonstrated by: MRI or two or more MRI-detected lesions consistent with MS plus positive CSF and dissemination in time, demonstrated by: MRI or second clinical attack, OR
- Insidious neurological progression suggestive of MS, one year of disease progression (retrospectively or prospectively determined) and two of the following:
  1. Positive brain MRI (nine T2 lesions or four or more T2 lesions with positive VEP)
  2. Positive spinal cord MRI (two focal T2 lesions)
  3. Positive CSF